Stay updated on Selpercatinib in RET+ NSCLC Clinical Trial
Sign up to get notified when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.

Latest updates to the Selpercatinib in RET+ NSCLC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check15 days agoChange DetectedThe web page has updated its date information, adding new dates in April 2025 while removing older dates from February 2025.SummaryDifference0.3%
- Check23 days agoChange DetectedThe page has been updated to include new information about the drug Pemetrexed and Pembrolizumab, along with a new revision number. The previous study details regarding selpercatinib and its comparison to standard treatments have been removed.SummaryDifference9%
- Check30 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 27, 2025, while a previous date of March 25, 2025, has been removed.SummaryDifference0.2%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 27, 2025, to March 25, 2025.SummaryDifference0.1%
- Check66 days agoChange DetectedThe webpage has updated its date references, removing older dates from January 2025 and adding new dates in February 2025.SummaryDifference0.3%
Stay in the know with updates to Selpercatinib in RET+ NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Selpercatinib in RET+ NSCLC Clinical Trial page.